The Library
FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer
Tools
Tools
Tools
(2020) FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer. British Journal of Cancer, 122 . pp. 361-371. doi:10.1038/s41416-019-0649-5 ISSN 0007-0920.
|
PDF
WRAP-FKBPL-based-peptide-angiogenesis-cancer-stem-cells-cancer-Marshall-2019.pdf - Accepted Version - Requires a PDF viewer. Download (1259Kb) | Preview |
Official URL: http://dx.doi.org/10.1038/s41416-019-0649-5
Abstract
Background
ALM201 is a therapeutic peptide derived from FKBPL that has previously undergone preclinical and clinical development for oncology indications and has completed a Phase 1a clinical trial in ovarian cancer patients and other advanced solid tumours.
Methods
In vitro, cancer stem cell (CSC) assays in a range of HGSOC cell lines and patient samples, and in vivo tumour initiation, growth delay and limiting dilution assays, were utilised. Mechanisms were determined by using immunohistochemistry, ELISA, qRT-PCR, RNAseq and western blotting. Endogenous FKBPL protein levels were evaluated using tissue microarrays (TMA).
Results
ALM201 reduced CSCs in cell lines and primary samples by inducing differentiation. ALM201 treatment of highly vascularised Kuramochi xenografts resulted in tumour growth delay by disruption of angiogenesis and a ten-fold decrease in the CSC population. In contrast, ALM201 failed to elicit a strong antitumour response in non-vascularised OVCAR3 xenografts, due to high levels of IL-6 and vasculogenic mimicry. High endogenous tumour expression of FKBPL was associated with an increased progression-free interval, supporting the protective role of FKBPL in HGSOC.
Conclusion
FKBPL-based therapy can (i) dually target angiogenesis and CSCs, (ii) target the CD44/STAT3 pathway in tumours and (iii) is effective in highly vascularised HGSOC tumours with low levels of IL-6.
| Item Type: | Journal Article | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Subjects: | Q Science > QH Natural history Q Science > QP Physiology R Medicine > RC Internal medicine |
||||||||||||||||||||||||
| Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Clinical Trials Unit Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||||||||||||||||||||||
| Library of Congress Subject Headings (LCSH): | Ovaries -- Cancer , Ovaries -- Cancer -- Treatment, Vascular endothelial growth factors, Cancer cells , Stem cells | ||||||||||||||||||||||||
| Journal or Publication Title: | British Journal of Cancer | ||||||||||||||||||||||||
| Publisher: | Nature Publishing Group | ||||||||||||||||||||||||
| ISSN: | 0007-0920 | ||||||||||||||||||||||||
| Official Date: | 4 February 2020 | ||||||||||||||||||||||||
| Dates: |
|
||||||||||||||||||||||||
| Volume: | 122 | ||||||||||||||||||||||||
| Page Range: | pp. 361-371 | ||||||||||||||||||||||||
| DOI: | 10.1038/s41416-019-0649-5 | ||||||||||||||||||||||||
| Status: | Peer Reviewed | ||||||||||||||||||||||||
| Publication Status: | Published | ||||||||||||||||||||||||
| Access rights to Published version: | Open Access (Creative Commons) | ||||||||||||||||||||||||
| Date of first compliant deposit: | 4 December 2019 | ||||||||||||||||||||||||
| Date of first compliant Open Access: | 27 May 2020 | ||||||||||||||||||||||||
| RIOXX Funder/Project Grant: |
|
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
Downloads
Downloads per month over past year
